We are a VC fund focused on investing in early-stage companies in the healthcare sector: biotechnology, medical devices and eHealth.
Invivo Ventures is managed by Invivo Capital Partners, promoted by Luis Pareras and Albert Ferrer, with the experience gained through the first fund Healthequity. The fund was registered to the Comisión Nacional del Mercado de Valores (CNMV) in March 2019 and has achieved a final closing of 60M €.
We are a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. We also have a network of contacts and key strategic relationships in the health ecosystem.
Our company is financed by the European Investment Fund, the Instituto de Crédito Oficial, the Institut Català de Finances, the Institut Valencià de Finances and other private investors.
We seek projects according to the following criteria:
We set initial investments in the range of 0.5-2M €, and after achieving pre-established milestones we can reach up to 4M €.
State of development
We focus on investing in companies in early stages, mainly in the technology transfer phase. In the case of biotechnology companies, they should have a solid proof of concept in animal models, and in the case of medical devices or digital health companies, a prototype close to the market.
We invest in Spain a significant amount of the funds raised, while a smaller percentage is considered for investments syndicated with other funds in European companies.
We want to diversify risks by investing in companies in different stages and different sub-sectors within the biomedical area, such as biotechnology, medical devices and digital health.
Healthequity is a VC fund focused on investing in early-stage companies in the Healthcare sector. Promoted by the Medical Association of Barcelona and the financial group Riva y Garcia, it was registered with the CNMV and founded in 2012.
The fund finished its first investment period in early 2019.
Minoryx is a biotechnology company committed to finding innovative treatments for life threatening rare diseases, currently focused on Inborn Errors of Metabolism.
SANIFIT is a biotechnology company focused on treatments for calcification disorders. Their lead product SNF472 commenced phase I clinical trials in early 2014.
nLife Therapeutics is a biotechnology company leading the discovery and development of oligonucleotides as therapeutic agents for those CNS disorders where unmet medical needs are not covered by traditional treatments.
Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment.
Versantis is a pharmaceutical company specialized in the development of products aimed at unmet medical needs in the diagnosis, prevention and treatment of liver diseases.
GlyCardial Diagnostics is a company that aims to develop a "laboratory-based" in vitro diagnosis (IVD) test to detect Apo J-Glyc in blood as a promising biomarker for the early diagnosis of cardiac ischemia and the prediction of patient's evolution after an ischemic event.
ARTHEx Biotech is a spin-off company from the University of Valencia, with a strong background on microRNAs involvement in neuromuscular diseases. The company is focused on the development of RNA treatments against genetic diseases. The lead candidate, ATX-01, is an antimiR-based treatment against Myotonic Dystrophy Type I.
Pulmobiotics aims to develop new biotherapeutic drugs to treat lung infections using synthetic biology tools.
Gyala Therapeutics is a spin off from Hospital Clínic – IDIBAPS (Barcelona) focused on developing new CAR-T therapies for treating hematological malignancies.
Telum Therapeutics provides a Platform to develop Phage-encoded endolysins as bactericidal agents for multi-drug resistant infections. According to WHO, antimicrobial resistance is an increasingly serious threat to global public health.
OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.
Telomere Therapeutics is a spin-off company from CNIO and UAB, that aims to develop a gene therapy approach to express the TERT gene to treat Idiopathic Pulmonary Fibrosis, based on the research of the co-founders Dr. Maria Blasco and Dr. Fàtima Bosch.
Degree and PhD in Medicine (UB), specialist in Neurosurgery and Global Executive MBA (IESE).
Founding Partner of two Venture Capital funds (Healthequity and Invivo Ventures) focused in early-stage investments in the healthcare sector, where he has led the investment strategy and transaction processes.
He serves or has served at the Board of Directors of many life-sciences companies including Sanifit, Minoryx, Versantis, Glycardial Diagnostics, n-Life Therapeutics, Peptomyc, Arthex, Pulmobiotics, Gyala, Telum, OneChain Immunotherapeutics and Telomere Therapeutics.
Deeply involved in the innovation ecosystem, he is a member and advisor of many healthcare innovation organizations, and author of numerous books in the field of innovation, venture capital and healthcare.
In the academic space, he teaches at several business schools about healthcare innovation and venture capital.
He founded the managing company Invivo Capital Partners together with Albert Ferrer.
Degree in Business Administration and MBA from ESADE, Master CEMS (Community of European Management Schools) in Management from HEC – Hautes Études Commerciales (París) and Chartered Financial Analyst (CFA).
He has been involved in the Spanish VC industry for the past 20 with a focus on high-growth, early stage, technology centered investments.
Member of the board of directors of different portfolio companies: Arthex, Pumobiotics, Gyala, Telum, OneChain Immunotherapeutics and Telomere Therapeutics.
He is as well currently Director of Healthequity, a venture capital fund focused in early-stage companies in the healthcare sector, where he led the investment strategy and transaction processes of the different portfolio companies. He has been a member of the Board of Directors of different life-sciences companies and of Healthequity's investments: Sanifit, Peptomyc and Glycardial Diagnostics.
Previously, he led Spinnaker Invest, VC firm within Grupo Financiero Riva y García. He has been as well a member of the Board of Directors of various companies such as Exoticca, Wecare-u and Scytl.
He founded the managing company Invivo Capital Partners together with Luis Pareras.
Bachelor of Science in Biotechnology (UAB), PhD in Biotechnology (UB) and a Postgraduate course in Innovation Management (UAB).
Her research in gene therapy applications in the cancer field have led to publications in scientific journals and collaborations with biotech companies.
She has been Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona.
She is an active member in the EIT Health Alumni Network, after her participation in the EIT Health Innovation & Business Creation Summer School (2016) organized by the Trinity College in Dublin and IESE business school.
She usually collaborates with different entities of the health innovation ecosystem as a start-up mentor, jury and evaluator (COMB, EIT Health, Ship2b, Imagine IF!, FIPSE and CIMTI, among others).
Since January 2018, she works as investment analyst in Healthequity, and since 2019 at Invivo Ventures, the first fund of Invivo Capital Partners.
She’s Observer at the Board of Arthex, Pulmobiotics, Gyala, Telum, OneChain Immunotherapeutics and Telomere Therapeutics.
Currently she is Principal at Invivo Capital Partners.
BSc & MSc Civil and transport Engineering (UPC) and BSc Economics (UB).
He has worked in the financial and operations department of the technologic start-up Exoticca, collaborating in the fundraising of the company, and in n a financial boutique specialized in M&A from the Spanish industrial sector.
Moreover, he has consulting experience in the financial, engineering and market intelligence consulting sectors.
Since April 2019, he works as an Investment analyst in Healthequity and Invivo Ventures, Invivo Capital Partners first fund.
Bachelor of Science in Biomedical Sciences (UB), Master of Science in Business Management applied to the Biotechnology Sector and Pharmaceutical Industry, specialized in Project Management (BBI) and Postgraduate course in Financing (UPF Barcelona School of Management).
She has been Project Manager in UPF Ventures, an innovation management firm owned by Universitat Pompeu Fabra (UPF).
She is member of the EIT Health Alumni Network, after her participation in the StarShip Program (2019) organized by EIT Health in collaboration with leading European universities (University of Oxford, IESE Business School) and industrial partners (GE Healthcare).
She usually collaborates with different entities of the health innovation ecosystem as an innovation projects and start-up evaluator (COMB, EIT Health, CIMTI, The Collider, among others),
Since May 2020, she works as an Investment Analyst at Invivo Ventures, the first fund of Invivo Capital Partners.
For 18 years she worked at the Barcelona Medical Association. Since 2012, when Healthequity was founded, she has worked as Office Manager and Executive Assistant carrying out administration tasks, client and supplier relations, agenda, conference and travel planning and management, both for the directors and the team, as well as managing events like the Healthcare Investment Forums and the Ready4Growth seminars.
She currently works at Invivo Capital as Executive Assistant, Office Manager and Social Media Manager.
Here’s a map of some of the most promising research fields in oncology today, plus a video —below— with some advice for scientists willing to become entrepreneurs (from a debate on the future of oncology and how to make it happen)
One of the most important things every investor looks for in a startup is a good problem to solve… Unanswered questions always signal what’s next. Here’s a map of some of the most pressing questions in the oncology field today.
Fund financed by FEDER: